Current and future immunotherapy targets in autoimmune neurology

Area of Science:

• Neurology
• Immunology
• Clinical Therapeutics

Background:

• Limited randomized controlled trials exist for autoimmune neurologic disorders.
• Treatment data primarily comes from expert opinion, case series, and anecdotal reports.
• Current treatments include oncologic therapy and immunotherapy.

Purpose of the Study:

• To provide a practical overview of standard acute and chronic immunotherapies.
• To discuss novel treatment approaches for autoimmune neurologic disorders.
• To highlight the importance of individualized treatment strategies.

Main Methods:

• Review of standard immunotherapies, including mechanisms, dosing, monitoring, and side effects.
• Discussion of novel treatment strategies, focusing on monoclonal antibodies.
• Case examples of myasthenia gravis, neuromyelitis optica, and chronic inflammatory demyelinating polyradiculoneuropathy.

Main Results:

• Standard immunotherapies offer established acute and chronic treatment options.
• Novel approaches, particularly monoclonal antibodies, show promise but require better understanding of immunopathology.
• Individualized treatment is crucial, influenced by clinical severity, antibody type, cancer status, and prior response.

Conclusions:

• Effective management of autoimmune neurologic disorders requires a comprehensive understanding of available therapies.
• Personalized treatment plans are essential for optimizing patient outcomes.
• Further research into immunopathology will drive the development of new therapeutic strategies.